Non-Small Cell Lung Cancer
Cancer-associated weight loss is linked to worse survival outcomes among patients with cancer.
The safety profile of each agent was consistent with those previously reported.
Researchers evaluated whether different complex mutations lead to different clinical outcomes among patients treated with EGFR-TKIs.
Efforts are underway to develop predictive molecular biomarkers that can improve patient selection for ICIs.
Previous studies demonstrated that fruquintinib may have clinical value for patients who fail at least 2 prior lines of therapy.
The FDA based its approval on positive findings from the phase 3 PACIFIC study.
Researchers are evaluating whether avelumab, a PD-L1 inhibitor, is safe and effective in combination with chemotherapy for treating patients with NSCLC or urothelial cancer.
Living in a lower-education area and being African American were associated with not receiving any cancer-directed care.
PSPT significantly reduced radiation exposure to the heart, but no differences were observed between PSPT and IMRT for the lung or esophagus.
Researchers are evaluating whether patients with metastatic NSCLC will benefit from stereotactic body radiation and a virally mediated gene therapy prior to nivolumab.
One trial is evaluating whether an HDAC inhibitor, mocetinostat, in combination with a demethylating drug, guadecitabine, can boost responses to pembrolizumab in patients with advanced NSCLC.
Data from previous studies suggest that adjuvant chemotherapy and PORT may improve patient outcomes, but the optimal sequence of administration was previously unestablished.
Researchers are evaluating whether Ad5-yCD/mutTKSR39rep-ADP, an oncolytic adenovirus, can help to improve outcomes among patients with inoperable stage I/IIA NSCLC.
SBRT provides excellent local control and an adequate safety profile, but there is a lack of data comparing SBRT to resection among patients eligible for surgery.
Researchers are evaluating the safety and efficacy of pembrolizumab in combination with a synthetic long peptide vaccine among patients with non-small cell lung cancer.
Researchers are assessing the safety and efficacy of lorlatinib among patients with ROS1 and ALK mutation-positive NSCLC that has metastasized to the CNS.
Researchers are assessing the efficacy of neoadjuvant pembrolizumab with or without low-dose SRT among patients with stage I to IIIA NSCLC who plan to undergo surgical resection.
Researchers are evaluating the safety and efficacy of a vaccine for patients with resectable NSCLC.
Researchers enrolled 222 patients with completely resected stage II-IIIA (N1-N2) NSCLC to receive adjuvant gefitinib or cisplatin plus vinorelbine.
Researchers evaluated the biopsies and outcomes of 5 patients with an EGFR-activating mutation who were initially treated with a first- or second-generation EGFR-TKI.
Investigators randomly assigned 1501 patients with completely resected stage IB to IIIA NSCLC to receive chemotherapy alone or chemotherapy plus bevacizumab.
The discovery of molecular biomarkers and EGFR mutations have shifted the management of NSCLC from traditional cytotoxic chemotherapies towards precision medicine with TKIs.
c-MET, although rarer than T790M, may be a promising therapeutic target for patients who progress on EGFR TKI therapy.
Approval was based on results from ALEX, for which researchers randomly assigned 303 patients with ALK-positive NSCLC not previously treated with systemic therapy to receive alectinib or crizotinib.
Several ongoing clinical trials are also evaluating durvalumab as a single agent or in combination with other therapies, such as tremelimumab, and as a first-line therapy.
Liquid biopsy can be useful in cases where small bronchial biopsies contain a low number of tumor cells, and the repeatability of liquid biopsies can offer new approaches for monitoring patients treated with immunotherapy.
For the phase 3 KEYNOTE-024 study, researchers randomly assigned 305 patients with advanced NSCLC of any histological type to 35 cycles of pembrolizumab or 4 to 6 cycles of investigator's choice chemotherapy.
At the closing plenary session of WCLC, Paul A. Bunn, Jr, MD, presented a treatment algorithm for lung cancer and discussed where lung cancer research in North America is heading.
A previous analysis of the phase 2 BIRCH study showed that atezolizumab, a PD-L1 inhibitor, provides clinically meaningful and durable benefit as a first- and second-line therapy.
ctDNA next generation sequencing of patient blood samples detected oncogenic drivers in 27 (36%) patients, including HER2 exon 20 insYVMA, BRAF L597Q, and MET exon14 mutations.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy